Biosimilars (or Follow on Biologics) are protein therapeutics that are intended to be substitutable for existing branded biologic products. Because true replication of the existing protein drug cannot be established the term “biogenerics” is not appropriate for these products. Hence the use of the term “biosimilars”.
ICON can support the complete development of Biosimilars/Follow-on Biologics. We have the required expertise to assist in product design, development and registration, regulatory support and commercialisation. Our portfolio includes:
Strategic Planning and Design
Product portfolio reviews
Current products, indications and associated exclusivities
Competitive landscape / Future market assessment
New Product Concepts
Due diligence for product acquisition
Product Development Planning:
Strategic development options to Proof of Concept, Regulatory Submission or other development milestones
Issues assessment and mitigation strategies
Nonclinical/Clinical development strategies
Regulatory enabling strategies, including scientific advice and pediatric plans
Product Development Capabilities
Non-clinica/Preclinical development
In vitro studies
In vivo studies
Bioanalytical
Non-clinical and clinical assay support
PK assays for comparability testing v Approved Biologics
Immunogenicity testing
Biomarker assays
Non-clinical development, Drug Quality
Physico-chemical testing
Drug substance and drug product comparability
Formulation development and characterization
Stability testing
Clinical efficacy and safety
PK/PD assessments including comparison to reference products